AbbVie 2013 Annual Report Download - page 154

Download and view the complete annual report

Please find page 154 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

The named executive officers also are eligible to participate in an executive disability benefit
described in the section of this proxy statement captioned ‘‘Potential Payments upon Termination—
Generally.’’
(7) Bonus paid in recognition of performance related to the business Separation.
2013 Grants of Plan-Based Awards
The following table summarizes the AbbVie equity awards granted under the AbbVie 2013
Incentive Stock Program to the named executive officers during 2013.(1)
All Other
Estimated Future Estimated Option
Payouts Under Future Awards: Exercise Grant Date
Non-Equity Payouts Numbers of or Base Closing Fair Value
Incentive Plan Under Equity Securities Price of Market of Stock
Awards(2) Incentive Underlying Options Price on and
Grant Target Maximum Plan Awards Options Awards Grant Option
Name Date ($) ($) Target (#)(3)(4) (#) ($/Sh.) Date Awards
R. Gonzalez .... 02/14/13 257,720 $9,246,994(5)
02/14/13 526,430(6) $35.88 $36.57 3,616,574(7)
L. Schumacher . . 02/14/13 71,230 2,555,732(5)
02/14/13 145,510(6) 35.88 36.57 999,654(7)
08/16/13(8) 8,928 43.21 43.00 28,837
W. Chase ...... 02/14/13 56,700 2,034,396(5)
02/14/13 115,830(6) 35.88 36.57 795,752(7)
C. Alban ...... 02/14/13 56,700 2,034,396(5)
02/14/13 115,830(6) 35.88 36.57 795,752(7)
T. Richmond .... 02/14/13 42,610 1,528,847(5)
02/14/13 87,040(6) 35.88 36.57 597,965(7)
(1) When AbbVie separated from Abbott Laboratories on January 1, 2013, holders of outstanding
Abbott equity awards generally received (except to the extent prohibited by local law or required
by award agreement terms) an identical number of AbbVie equity awards to preserve the value of
the outstanding Abbott awards. The AbbVie awards resulted from an anti-dilution adjustment in
accordance with terms of the Abbott awards designed to preserve the value of the Abbott awards,
so these January 1, 2013 awards are not included in this table. Additional information about the
conversion of the Abbott equity awards in connection with the Separation is included in footnote
(1) to the 2013 Outstanding Equity Awards at Fiscal Year-End table.
(2) During 2013, each of the named executive officers participated in the AbbVie 2013 Performance
Incentive Plan. The annual cash incentive award earned by the named executive officer in 2013
under the plan is shown in the Summary Compensation Table in the column captioned
‘‘Non-Equity Incentive Plan Compensation.’’ No future pay-outs will be made with respect to the
2013 awards under the plan. The plan is described in greater detail in the section of this proxy
statement captioned ‘‘Compensation Discussion and Analysis—How Executive Pay Decisions Are
Made—Short-Term Incentives.’’
(3) These are performance-based restricted stock awards that have a five-year term and vest upon
AbbVie achieving a minimum return on equity target, with no more than one-third of the award
vesting in any one year. In 2013, AbbVie reached its minimum return on equity target and
one-third of each of the awards granted on February 14, 2013 vested on February 28, 2014. The
return on equity targets are described in the section of this proxy statement captioned
31